8th Jan 2016 07:28
LONDON (Alliance News) - Venn Life Sciences Holdings PLC Friday announced the resignation of its Non-Executive Chairman David Evans, as it said it expects to report revenue "at least" doubled from the previous year for 2015.
Venn Life Sciences provides services including drug development and clinical trial management for the pharmaceutical, biotechnology and medical device spaces.
The company said Evans has resigned "in line with his personal commitment to reduce the number of non-executive chairman roles currently undertaken."
Chief Executive Officer Tony Richardson will act as executive chairman in the interim period until a suitable replacement is found.
Venn said it expects to report 2015 revenue of at least double the EUR4.9 million it reported in 2014, and expects to have ended the year with a cash position of EUR3.4 million. The company attributed its performance to contract wins, as well as a "growing reputation for delivering excellence and ongoing expansion of our international coverage and service capabilities."
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Venn Life Sciences